These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29854306)

  • 1. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
    Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
    Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
    Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
    Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
    Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
    Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
    Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
    J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
    Stafman LL; Waldrop MG; Williams AP; Aye JM; Stewart JE; Mroczek-Musulman E; Yoon KJ; Whelan K; Beierle EA
    J Pediatr Surg; 2019 Jun; 54(6):1206-1213. PubMed ID: 30898394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
    Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
    Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
    Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
    PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
    Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
    Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
    Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
    Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.
    Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
    J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM Kinases in Multiple Myeloma.
    Wu J; Chu E; Kang Y
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
    Brunen D; García-Barchino MJ; Malani D; Jagalur Basheer N; Lieftink C; Beijersbergen RL; Murumägi A; Porkka K; Wolf M; Zwaan CM; Fornerod M; Kallioniemi O; Martínez-Climent JÁ; Bernards R
    Oncotarget; 2016 Jun; 7(25):37407-37419. PubMed ID: 27270648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
    Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
    Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.
    Bownes LV; Julson JR; Quinn CH; Hutchins SC; Erwin MH; Markert HR; Stewart JE; Mroczek-Musulman E; Aye J; Yoon KJ; Ohlmeyer M; Beierle EA
    J Pediatr Surg; 2023 Jun; 58(6):1145-1154. PubMed ID: 36907775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIM Kinase as an Executional Target in Cancer.
    Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
    J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.